Zusammenfassung
Das kardiorenale Syndrom (CRS) findet sich im Krankheitsgut sowohl von Notaufnahmen, von Intensivstationen, insgesamt von Krankenhäusern, aber auch in Arztpraxen zunehmend häufiger. Ursache ist die demografische Entwicklung mit multimorbiden Patienten aufgrund kardiovaskulärer Risikokonstellationen. Oftmals bedingt eine Herzerkrankung auch eine Nierenerkrankung und umgekehrt. Das Management dieser Patienten ist schwierig, insbesondere da sich häufig widerstreitende Therapieziele finden. Für Nierenerkrankungen (CKD) gilt, dass diese kardiovaskuläre Risikofaktoren nicht nur leicht verstärken, sondern oftmals multiplizieren bis hin zu einer 100-fach höheren Erkrankungsrate an kardiovaskulären Erkrankungen (CVD). Weiterhin ist festzuhalten, dass eine CKD einen alleinigen kardiovaskulären Risikofaktor darstellt und derzeit in westlichen Industrieländern z. B. einen Diabetes mellitus als Risikofaktor für CVD deutlich überholt hat. Dies findet jedoch noch keinen Niederschlag im Bewusstsein von Patienten und Ärzten. Patienten mit CRS bedürfen modifizierter Therapien im Vergleich zu Patienten mit CVD ohne CKD. Die Therapieziele sind unterschiedlich, und Ergebnisse aus Studien mit Nierengesunden können nicht einfach auf diese Population extrapoliert werden.
Abstract
The cardiorenal syndrome (CRS) is seen in increasing numbers in emergency rooms, intensive care units, hospitals as a whole and outpatient departments. This is caused by the demographic shifts that lead to increasing numbers of elderly patients with multimorbidities. Often a heart disease is causing kidney failure and vice versa. The management of these patients is difficult due to the fact that often the goals of therapy are opposite. Patients with chronic kidney disease (CKD) have a 100-fold increased risk for the development of cardiovascular diseases (CVD). CKD alone is an important cardiovascular risk factor and has surpassed diabetes mellitus as a risk factor by far. However, awareness of this is low among doctors and patients. The treatment of patients with CRS is different from patients with CVD alone. The goals of therapy are different and the findings of studies in patients with CVD without CKD cannot simply be extended to these patients.
Literatur
Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038–2047
Plantinga LC, Boulware LE, Coresh J et al (2008) Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med 168:2268–2275
Palmer AJ, Valentine WJ, Chen R et al (2008) A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 23:1216–1223
Postma MJ, Boersma C, Gansevoort RT (2008) Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. Nephrol Dial Transplant 23:1103–1106
Moore SG, Shenoy PJ, Fanucchi L et al (2009) Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res 9:9
Ehlers L, Overvad K, Sorensen J et al (2009) Analysis of cost effectiveness of screening Danish men aged 65 for abdominal aortic aneurysm. BMJ 338:b2243
Xie F, O’Reilly D, Ferrusi IL et al (2009) Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol 6:317–323
Ronco C, House AA, Haapio M (2008) Cardiorenal and renocardiac syndromes: the need for a comprehensive classification and consensus. Nat Clin Pract Nephrol 4:310–311
Bellomo R, Ronco C, Kellum JA et al (2004) Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204–R212
Mehta RL, Kellum JA, Shah SV et al (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31
Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16–S23
Yamamoto S, Kon V (2009) Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr Opin Nephrol Hypertens 18:181–188
Weissberg PL, Bennett MR (1999) Atherosclerosis – an inflammatory disease. N Engl J Med 340:1928–1929
Covic A, Kothawala P, Bernal M et al (2009) Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 24:1506–1523
Schiele F (2009) Renal dysfunction and coronary disease: a high-risk combination. J Nephrol 22:39–45
Mathew S, Tustison KS, Sugatani T et al (2008) The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 19:1092–1105
Wen CP, Cheng TY, Tsai MK et al (2008) All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371:2173–2182
Campbell RC, Sui X, Filippatos G et al (2009) Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study. Nephrol Dial Transplant 24:186–193
Charytan DM, Kuntz RE, Garshick M et al (2009) Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney Int 75:80–87
Bax L, Algra A, Mali WP et al (2008) Renal function as a risk indicator for cardiovascular events in 3216 patients with manifest arterial disease. Atherosclerosis 200:184–190
Yusuf S, Teo KK, Pogue J et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559
Phillips CO, Kashani A, Ko DK et al (2007) Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 167:1930–1936
Wanner C, Krane V, Marz W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248
Strippoli GF, Navaneethan SD, Johnson DW et al (2008) Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336:645–651
Chonchol M, Benderly M, Goldbourt U (2008) Beta-blockers for coronary heart disease in chronic kidney disease. Nephrol Dial Transplant 23:2274–2279
Holman RR, Paul SK, Bethel MA et al (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
Mehrotra R, Kathuria P (2006) Place of peritoneal dialysis in the management of treatment-resistant congestive heart failure. Kidney Int Suppl S67–S71
Schrier RW (2007) Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 3:637
Kramer P, Schmidt-Lauber M, Langenheim N et al (1980) Reno-cardiac interactions in kidney failure (author’s transl). Klin Wochenschr 58:1043–1050
Mishra J, Dent C, Tarabishi R et al (2005) Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365:1231–1238
Cai L, Borowiec J, Xu S et al (2009) Assays of urine levels of HNL/NGAL in patients undergoing cardiac surgery and the impact of antibody configuration on their clinical performances. Clin Chim Acta 403:121–125
Martin-Llahi M, Pepin MN, Guevara M et al (2008) Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 134:1352–1359
Sanyal AJ, Boyer T, Garcia-Tsao G et al (2008) A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134:1360–1368
Gluud LL, Kjaer MS, Christensen E (2006) Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev CD005162
Lip GY, Beevers M, Beevers DG (1997) Does renal function improve after diagnosis of malignant phase hypertension? J Hypertens 15:1309–1315
Ronco C, Chionh CY, Haapio M et al (2009) The cardiorenal syndrome. Blood Purif 27:114–126
Parikh CR, Jani A, Mishra J et al (2006) Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 6:1639–1645
Frei U, Schober-Halstenberg H-J (2008) Nierenersatztherapie in Deutschland. Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2006I2007
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alscher, M. Herz und Niere. Kardiologe 3, 489–498 (2009). https://doi.org/10.1007/s12181-009-0219-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12181-009-0219-9
Schlüsselwörter
- Niereninsuffizienz
- Akutes Nierenversagen
- Kardiorenales Syndrom
- Kardiovaskuläre Erkrankungen
- Risikostratifikation